Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele ( Kras G12D ) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of Kras G12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, Kras G12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4196.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“In a mouse model, CDKN2A loss accelerated KRASG12D-driven tumor growth54.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [54]
In the citing paper
“GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [74]
In the citing paper
“combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Although ARF is a known activator of the p53 pathway (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) and its loss clearly attenuates the function of that critical tumor suppressor, more recent studies have demonstrated that ARF has p53-independent…”
BackgroundSelf-citationGu, G., Dubauskaite, J., & Melton, D. A. (2002) · Development · doi:10.1242/dev.129.10.2447 · Cited by 1,518
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Warshaw, A. L., & Castillo, C. F.-D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260706 · Cited by 1,198
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Research works printed but not linked: 17
- 2003, Cancer Res., 63, 2005
- 1976, Cancer Res., 36, 2690
- 1990, Mol. Cell. Biol., 10, 1779
- 1992, Am. J. Pathol., 140, 1237
- 2003, Cancer Res., 63, 2016
- 2001, Cancer Res., 61, 4923
- 1994, Am. J. Pathol., 145, 1547
- 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O · doi:10.1002/(sici)1098-2264(200004)27:4<358::aid-gcc4>3.0.co;2-o
- 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R · DOI
- 2001, Cancer J., 7, 242
- 1997, Cancer Res., 57, 2140
- 1997, Cancer Res., 57, 1731
- 1998, Biochim. Biophys. Acta, 1378, F115
- 1998, Cancer Res., 58, 4740
- 2000, Cancer Res., 60, 2002
- 1986, Jpn. J. Cancer Res., 77, 370
- 1994, Am. J. Pathol., 145, 671
Cited by
Items 901–999 of 999
El ratolí com a sistema model en biologia
Merlos‐Suárez, A. (2011) · RACO (Revistes Catalanes amb Accés Obert) (Consorci de Serveis Universitaris de Catalunya)
Song, X. (2011) · Digital Commons-TMC (Texas Medical Center)
Role of the Ink4a/Arf tumor suppressors in cerebellar development, stem cells and cancer
Lingbeek, M. (2005) · Utrecht University Repository (Utrecht University)
Winograd, R. (2015) · ScholarlyCommons (University of Pennsylvania)
Chang, Z. (2011) · Digital Commons-TMC (Texas Medical Center)
Pearson, H. (2003) · Nature · doi:10.1038/news031208-12
Well-Differentiated Thyroid Follicular Carcinoma
Kroll, T. G. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-1707-2_9
Aichler, M. (2008) · Site cant be reached · Cited by 1
Qian, J., Yang, H. B., Li, J., & Wang, J. (2012) · InTech eBooks · doi:10.5772/28982
“found that p16 limits the malignant conversion of these PanIN lesions to ductal adenocarcinoma in activated KRAS-initiated PanIN formation, which suggested that p16 is not the earliest event but is an important event in the progression of pancreatic carcinogenesis (Aguirre et al., 2003).”
Pancreatic Carcinoma: An Introduction
Hayat, M. A. (2005) · Handbook of immunohistochemistry and in situ hybridization of human carcinomas · doi:10.1016/s1874-5784(05)80033-9 · Cited by 1
Methylation Detection and Epigenomics in Pancreatic Cancer
Feldmann, G., & Maitra, A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1160-5_10
Pancreatic cancer: making progress
Flintoft, L. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1266
Examining the Role of Hedgehog Signaling in the Pancreatic Tumor Microenvironment.
Dosch, J. S. (2011) · Deep Blue (University of Michigan)
Schmittgen, T. D., & Azevedo‐Pouly, A. C. P. (2014) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s38297
“Mutations in KRAS almost exclusively occur in codons 12, 13, and 61.(87) KRAS and other Ras”
BackgroundGenetically-engineered mouse pancreatic cancer models
Ijichi, H. (2010) · Suizo · doi:10.2958/suizo.25.28
Tumorigenesis: Modeling Kras in cells and mice
Gurumurthy, S., & Bardeesy, N. M. (2006) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2006.05.008
Self-citationMouse model of pancreatic ductal adenocarcinoma:an update
Wang, W. (2008) · Academic Journal of Second Military Medical University · doi:10.3724/sp.j.1008.2008.00435
Satoh, K., Kimura, K., Kanno, A., Hamada, S., Hirota, M., & Shimosegawa, T. (2009) · Pancreas · doi:10.1097/01.mpa.0000357026.62050.25
Mechanisms of KRAS-Mediated Pancreatic Tumor Formation and Progression: A Dissertation
Appleman, V. A. (2012) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/ekp2-9e89
Med29 Possesses a Complex Role in Pancreatic Cancer
Kuuselo, R. (2010) · Tampere University Institutional Repository (Tampere University)
Zhu, M., Michalowski, A. M., & Green, J. E. (2011) · Springer eBooks · doi:10.1007/978-0-387-69805-2_10
The Genetics of Pancreatic Cancer Progression
Iacobuzio–Donahue, C. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6549-2_8 · Cited by 1
The Role of the Rho GEF Arhgef2 in RAS Tumorigenesis
Cullis, J. E. (2013) · TSpace (University of Toronto)
Inhibition of Pancreatitis and Carcinogenesis by Capsaicin
Zhang, W., Liao, J., Li, H., Yang, A. L., Srivastava, S., & Yang, G. (2013) · Springer eBooks · doi:10.1007/978-94-007-6317-3_5
Genomic Alterations in Sporadic Pancreatic Cancer
Molin, M. D., & Maitra, A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6549-2_1
ZNF300 may influence the metastatic properties in pancreatic ductal adenocarcinoma
Fisher, A. (2014) · Library, Museums and Press - UDSpace (University of Delaware) · doi:10.58088/20w0-a371
Gene regulatory and pro-tumourigenic mechanisms of the bHLH-PAS transcription factor SIM2s.
Farrall, A. L. (2010) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Baumgart, M. (2010) · Kobra (Universitätsbibliothek Kassel)
Segarra-Martínez, A. J. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
The role of PAK4 in pancreatic cancer
King, H. A. (2014)
Epigenome modifying enzymes regulate development and progression of pancreatic cancers
Tateishi, K., Yamamoto, K., & Koike, K. (2016) · Suizo · doi:10.2958/suizo.31.69
Signaling Cross-Talk of Oncogenic KRAS and Hedgehog Pathways in Pancreatic Cancer
Cheng, X. (2011) · Springer eBooks · doi:10.1007/978-1-4419-8435-7_5
“For example, targeted endogenous expression of an oncogenic KRAS allele in the mouse pancreas is sufficient to drive the development of PanINs and subsequently at low frequency the progression to both locally invasive adenocarcinoma and metastatic disease with sites of spread exactly as found in human PDA [ 1 , 28].”
BackgroundTransforming Growth Factor-β Signaling in Pancreas Development and Pancreatic Disease
Rane, S. G., Lin, H., & Lee, J.-H. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-293-9_1
Current state of the evolving MMMN cancer progression models of cancer
Thiagalingam, S. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9780511979811.022
Strategies to Target Pancreatic Cancer
Liou, G., & Störz, P. (2016) · Springer eBooks · doi:10.1007/978-3-319-31254-5_1
Molecular Pathogenesis of Pancreatic Adenocarcinoma
Shroff, R. T., & Abbruzzese, J. L. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00035-4
Cross Talk Between Snail and Mutant K-Ras Contributes to Pancreatic Cancer Progression
Chow, C. R., Ebine, K., Hattaway, H. Z., Kumar, K., & Munshi, H. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00007-2 · Cited by 1
MEK inhibition in pancreas cancer
Vena, F. (2016) · UCL Discovery (University College London)
Oncogenic KRAS and the Inflammatory Micro-Environment in Pancreatic Cancer
Chang, H.-H., Schmidt, A., & Eibl, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803505-4.00005-9
Polireddy, K. (2015) · KU ScholarWorks (The University of Kansas)
Mouse Models of Pancreatic Exocrine Cancer
Pérez-Mancera, P. A. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_77-1
Deciphering the role of SerpinB2 in cancer invasion and metastasis
Harris, N. L. E. (2017) · Research Online (University of Wollongong)
In Vitro Modeling of Pancreatic Duct Cell Carcinogenesis
Leung, L. (2014) · TSpace (University of Toronto)
Elucidating the role of SMAD7 in pancreatic cancer through in vivo studies
Savant, S. S. (2017) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1806
Immune responses against spontaneous tumors in a murine model for pancreatic adenocarcinoma
Garbe, A. I. (2004) · Digitale Bibliothek Braunschweig (Verbundzentrale Göttingen (VZG)) · doi:10.24355/dbbs.084-200511080100-385
Plentz, R. R., Rhim, A. D., Abravanel, D. L., Hezel, A. F., Sharma, S. V., Gurumurthy, S., Deshpande, V., Kenific, C. M., Settleman, J. E., Majumder, P. K., et al. (2009)
Self-citationSteins, A., Bijlsma, M. F., & van Laarhoven, H. W. M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811353-0.00054-3 · Cited by 2
Ager, C. R. (2018) · Digital Commons-TMC (Texas Medical Center)
Investigations into how best to target FGFR2 mutant endometrial cancer
Geng, X. (2017) · Queensland University of Technology · doi:10.5204/thesis.eprints.123437
Chemo-prevention and interception of obesity-promoted pancreatic ductal adenocarcinoma
Chang, H.-H., & Eibl, G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814704-7.00006-4
Role of MAPK Activation in Prostate Cancer Development and Progression
Jeong, H. (2008) · Defense Technical Information Center (DTIC) · doi:10.21236/ada484145
Regulation of the kRAS Promoter in Pancreatic Cancer by Proteins and Small Molecules
Batra, H. (2017) · ProQuest Demo Repository
Loss of TIP30 Accelerates Pancreatic Cancer Progression and Metastasis
Imasuen, I. (2019) · IUScholarWorks (Indiana University) · doi:10.7912/c2/1902
Molecular Pathogenesis of Pancreatic Adenocarcinoma
Xiong, H. Q., & Abbruzzese, J. L. (2008) · Elsevier eBooks · doi:10.1016/b978-141603703-3.10035-4
Li, D., Roeck, K., Zhang, C., Zidek, B., Rodman, E. P. B., Hernandez-Barco, Y. G., Zhang, J., Bamlet, W. R., Oberg, A. L., Zhang, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.14.202952
“crossbreeding with mutations/deletions of the tumor suppressors TP53 or Ink4a/Arf (29,30).”
BackgroundSelf-citationIovanna, J., Calvo, E. L., Dagorn, J. C., & Dusetti, N. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-358-5_5
Influence of Dietary Fat on the Development of Cancer
Glauert, H. P. (2008) · Food science and technology · doi:10.1201/9781420046649.ch25
Connor, A. A., Denroche, R. E., Jang, G. H., Lemire, M., Zhang, A. X. W., Chan‐Seng‐Yue, M., Wilson, G. W., Merico, D., Lungu, I. M., Bartlett, J. M. S., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3188387
Dong, R. (2020) · KU ScholarWorks (The University of Kansas)
Transposable element activity in the transcriptomic analysis of mouse pancreatic tumorsPreprint
Lerat, E., Burlet, N., Navratil, V., & Noûs, C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.16.452652
Tracing tumor evolution and subtype specification in pancreatic cancerPreprint
Rajbhandari, N., Hamilton, M., Quintero, C. M., Ferguson, L. P., Fox, R., Schürch, C. M., Wang, J., Nakamura, M., McDermott, M. L., Pettit, H. W., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-101578/v1
Jugniot, N., Bam, R., & Paulmurugan, R. (2021) · Research Square · doi:10.21203/rs.3.rs-646172/v1
Mutant K-Ras Mediated Oxidative Stress in Pancreatic Cancer
Thomas, D., Sagar, S., Caffrey, T., & Radhakrishnan, P. (2021) · Springer eBooks · doi:10.1007/978-981-15-4501-6_94-1
Furukawa, T. (2007) · PubMed · Cited by 1
Mouse Models of Pancreatic Exocrine Cancer
Lockley, M., & Tuveson, D. A. (2009) · Springer eBooks · doi:10.1007/978-0-387-77498-5_20
Self-citationIvakhno, S., Frese, K. K., Tavaré, S., Iacobuzio–Donahue, C. A., & Tuveson, D. A. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9780511979811.027
Self-citationThe Molecular Pathology of Precursor Lesions of Pancreatic Cancer
Singhi, A. D., & Maitra, A. (2017) · Springer eBooks · doi:10.1007/978-1-4939-6631-8_5-2
Faculty Opinions recommendation of Cell of origin influences pancreatic cancer subtype.
Sosa‐Pineda, B. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739647870.793585324
SATOH, K., Kimura, K., KANNO, A., Hamada, S., Hirota, M., & Shimosegawa, T. (2008) · Suizo · doi:10.2958/suizo.23.46
Genetics of Pancreatic Carcinogenesis: Current Molecular Insights from Animal Models
Veerabathiran, R., & Mohammed, V. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_28-1
Quelle, D. E., Nteeba, J., & Darbro, B. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.30060-8
Experimental Model for Pancreatic Cancer and Its Therapeutic Implications in Clinical Research
Jayaraman, S., Ponnusamy, B., Rajagopal, P., Kumar, S. G., & Chandrasekar, K. (2022) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-1282-5_39-1
Genetics of Pancreatic Carcinogenesis: Current Molecular Insights from Animal Models
Veerabathiran, R., & Mohammed, V. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_28
Militi, S., Liu, F., Nibhani, R., Mouti, M. A., Pook, M., Cai, L., Choo, S. W., & Pauklin, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3570401/v1
Gicquel, T., Marchianò, F., Reyes‐Castellanos, G., Audebert, S., Camoin, L., Habermann, B. H., Giannesini, B., & Carrier, A. (2024) · eLife · doi:10.7554/elife.93312.1 · Cited by 7
Identification of Ppy ‐lineage cells as a novel origin of pancreatic ductal adenocarcinoma
Pereye, O. B., Nakagawa, Y., Sato, T., Fukunaka, A., Aoyama, S., Nishida, Y., Mizutani, W., Kobayashi, N., Morishita, Y., Oyama, T., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6295
Identification of immune targeted molecules in pancreatic ductal adenocarcinoma
Raza, H., Ravinuthala, A., Hussain, S. Y., Nwachukwu, D., & Ali, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23523-8.00012-2
KRAS-driven cancer models for in vivo pharmacology and drug discovery
Chugh, S., Dow, L. E., Singh, M., & Aguirre, A. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00004-8
Self-citationLiot, S., Schmitter, C., Mercier‐Gouy, P., Kholti, N. E., Balas, J., Prigent, L., Aubert, A., Lethias, C., Chitty, J. L., Koch, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.07.635757
Canel, M., Lonergan, D. W., Ferguson, C., Gautier, P. E., Morton, J. P., von Kriegsheim, A., & Serrels, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.15.670486
Cho, W. H., Patel, A. J., Khudoynazarova, M., Warda, S., Yan, J., Li, D., Schoeps, D. M., Fishinevich, E., Pachai, M. R., Lee, C. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.12.687881
Cell of Origin and Mouse Models for Pancreatic Cancer
Means, A. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.04906-6
Genetically Engineered Mice Harboring RAS Mutations as Models of Human Cancer: in Medias RAS
Zaks, T. Z., Jacobetz, M. A., & Tuveson, D. A. (2006) · Springer eBooks · doi:10.1007/1-4020-4708-8_12
Self-citationImmunity and tolerance to the tumor-associated antigen MUC1
Ryan, S. O. (2009) · D-Scholarship@Pitt (University of Pittsburgh)
Molecular Regulators of Stem Cell Fate and Tumor Development in the Cerebellum
Brun, S. N. (2014) · DukeSpace (Duke University)
Mehta, S., Patel, I., & Patel, G. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118657
Rôle du stroma dans la progression de l'adénocarcinome pancréatique
Secq, V. (2014) · theses.fr (ABES) · doi:10.70675/3c4b7878z3e71z44fbza7f3zc5e1e99b02a2
Etude de la reprogrammation métabolique de l' adénocarcinome canalaire pancréatique
Olivares, O. (2015) · theses.fr (ABES) · doi:10.70675/ef2c6a2czab6dz4a68z8004z1ade8605dadc
Altérations moléculaires dans l'adénocarcinome du pancréas
Birnbaum, D. J. (2014) · theses.fr (ABES) · doi:10.70675/44add01bzd99bz4b1dzac77z13a6ea2ce322
Carmona, S. (2017) · theses.fr (ABES) · doi:10.70675/f95cdb23zecb6z4543z9164ze58fd37f2268
How are pancreatic tumors innervated?
Nguyen, T. T. H. (2017) · theses.fr (ABES) · doi:10.70675/cddec815z4e10z4727z99cez3311438335a2
Camus, M. (2017) · theses.fr (ABES) · doi:10.70675/4def68c4zdc9ez422eza783z692c3f1ea21e
Conséquences traductionnelles de la perte de 4E-BP1 dans l'adénocarcinome pancréatique
Müller, D. (2016) · theses.fr (ABES) · doi:10.70675/1f894fb2zc2daz446fza7f2z2b28408eb6e2
Analyse 3D des remodelages des réseaux neuronaux dans le cancer du pancréas
Lucchesi, A. (2018) · theses.fr (ABES) · doi:10.70675/ad846fa9z6d83z4bf4zb496zd84ac76097ad
Gouirand, V. (2018) · theses.fr (ABES) · doi:10.70675/fff49f3ezaf3bz4eaaz80f7z7dd647ad95a1
Metadata
- Authors
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Abramson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 24
- Pages
- 3112-3126
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC305262
- OpenAlex
- W2126663928
- Cited by
- 1,033
- References
- 84
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 67 · 2020: 46 · 2019: 45 · 2018: 46 · 2017: 55 · 2016: 49 · 2015: 63 · 2014: 69 · 2013: 67 · 2012: 53
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Lustgarten Foundation
- Dana-Farber Cancer Institute
- Barr Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, KRAS G12D, Ink4a/Arf, tumor suppressor inactivation, pancreatic intraepithelial neoplasia, premalignant pancreatic lesions, metastasis, mouse tumor model, tumor progression, stromal cell proliferation
- MeSH terms
- Animals, Fibroblasts, Humans, Mice, Transgenic, Pancreatic Neoplasms, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Viral Proteins, Tumor Suppressor Protein p53, Mice, Knockout, Integrases, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Suppressor Protein p14ARF, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.